Japan Intravenous Immunoglobulin Market Size & Outlook
Japan intravenous immunoglobulin market, 2018-2030 (US$M)
Related Markets
Japan intravenous immunoglobulin market highlights
- The Japan intravenous immunoglobulin market generated a revenue of USD 765.2 million in 2024 and is expected to reach USD 1,194.7 million by 2030.
- The Japan market is expected to grow at a CAGR of 7.7% from 2025 to 2030.
- In terms of segment, immunodeficiency diseases was the largest revenue generating application in 2024.
- Kawasaki Disease is the most lucrative application segment registering the fastest growth during the forecast period.
Intravenous immunoglobulin market data book summary
| Market revenue in 2024 | USD 765.2 million |
| Market revenue in 2030 | USD 1,194.7 million |
| Growth rate | 7.7% (CAGR from 2025 to 2030) |
| Largest segment | Immunodeficiency diseases |
| Fastest growing segment | Kawasaki Disease |
| Historical data | 2018 - 2023 |
| Base year | 2024 |
| Forecast period | 2025 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Immunodeficiency diseases, CIDP, Hypogammaglobulinemia, Congenital AIDS, Chronic Lymphocytic Leukemia, Myasthenia Gravis, Multifocal Motor Neuropathy, ITP, Kawasaki Disease, Guillain-Barre Syndrome |
| Key market players worldwide | Biotest AG ADR, Baxter International Inc, Grifols SA Ordinary Shares - Class A, CSL Ltd, Octapharma AG, LFB (Laboratoire Français du Fractionnement et des Biotechnologies), Taibang Biological Group, Kedrion Biopharma |
Other key industry trends
- In terms of revenue, Japan accounted for 5.5% of the global intravenous immunoglobulin market in 2024.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Asia Pacific, Japan intravenous immunoglobulin market is projected to lead the regional market in terms of revenue in 2030.
- China is the fastest growing regional market in Asia Pacific and is projected to reach USD 1,078.8 million by 2030.
Immunodeficiency diseases was the largest segment with a revenue share of 21.05% in 2024. Horizon Databook has segmented the Japan intravenous immunoglobulin market based on immunodeficiency diseases, cidp, hypogammaglobulinemia, congenital aids, chronic lymphocytic leukemia, myasthenia gravis, multifocal motor neuropathy, itp, kawasaki disease, guillain-barre syndrome covering the revenue growth of each sub-segment from 2018 to 2030.
Japan is experiencing significant growth in the IVIG market, driven by an increasing number of patients suffering from Myasthenia Gravis, CIDP, and Multifocal Motor Neuropathy. Hospital pharmacies and specialty pharmacies are the leading distribution channels, ensuring that patients across the country have access to IVIG treatments. International and local companies, including BDI Pharma Inc. and Octa pharma AG, are working to meet the growing demand for IVIG in Japan.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Intravenous Immunoglobulin Market Scope
Intravenous Immunoglobulin Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Japan intravenous immunoglobulin market size, by application, 2018-2030 (US$M)
Japan Intravenous Immunoglobulin Market Outlook Share, 2024 & 2030 (US$M)
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
